The PAH-SYMPACT questionnaire demonstrated high internal consistency (Cronbach's alpha > 0.80) and reproducibility (ICC 0.84-0.94) in a 16-week trial of 278 patients with PAH.
Why the study?
Does the PAH-SYMPACT questionnaire demonstrate valid and reliable psychometric properties in patients with pulmonary arterial hypertension?
Population
278 US patients with pulmonary arterial hypertension (PAH), 79% female, mean age 60 years
Design
Cohort
Follow-up
16 weeks
Key result
The PAH-SYMPACT questionnaire demonstrated high internal consistency (Cronbach's alpha > 0.80) and reproducibility (ICC 0.84-0.94) in a 16-week trial of 278 patients with PAH.
Authors
Discussion
Loading...
Member takes
Overview
Supports PAH-SYMPACT for symptom assessment in PAH research; leaves open routine clinical adoption.
Structured PICO
Does the PAH-SYMPACT questionnaire demonstrate valid and reliable psychometric properties in patients with pulmonary arterial hypertension?
P
Population
278 US patients with pulmonary arterial hypertension (79% female, mean age 60 years) participating in a 16-week single-arm trial of macitentan 10 mg.
I
Intervention
Macitentan 10 mg in a single-arm, 16-week trial (SYMPHONY) to validate the PAH-SYMPACT questionnaire
O
Outcome
Psychometric validation of the PAH-SYMPACT questionnaire (item performance, domain structure, internal consistency, test-retest reliability, construct validity, sensitivity to change)patient reported
The PAH-SYMPACT questionnaire is a valid, reliable, and sensitive disease-specific patient-reported outcome instrument for evaluating symptoms and impacts in patients with pulmonary arterial hypertension.
Cite This Study
Chin et al. (2018) studied Pulmonary Arterial Hypertension (n=278). Macitentan was evaluated on Psychometric validation including internal consistency and test-retest reliability. The PAH-SYMPACT questionnaire demonstrated high internal consistency (Cronbach's alpha > 0.80) and reproducibility (ICC 0.84-0.94) in a 16-week trial of 278 patients with PAH.